regdanvimab   Click here for help

GtoPdb Ligand ID: 11332

Synonyms: CT-P-59 | CT-P59 | Regkirona®
Approved drug
regdanvimab is an approved drug (South Korea & EMA (2021))
Compound class: Antibody
Comment: Regdanvimab (CT-P59) is a recombinant monoclonal antibody against the surface spike protein of SARS-CoV-2 [1]. It was developed by Celltrion. Regdanvimab inhibits SARS-CoV-2 infection via steric hindrance of its binding to human ACE2.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (South Korea & EMA (2021))
International Nonproprietary Names Click here for help
INN number INN
11883 regdanvimab
Synonyms Click here for help
CT-P-59 | CT-P59 | Regkirona®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1109
Other databases
GtoPdb PubChem SID 434321767
Search PubMed clinical trials regdanvimab
Search PubMed titles regdanvimab
Search PubMed titles/abstracts regdanvimab